These exciting new data support buntanetap’s unique mechanism of action of reducing over-expression of multiple neurotoxic proteins

[Farooqji]

“We are pleasantly surprised to see a statistically significant drop in TDP43 levels in just 10 patients and to see a strong trend in GFAP and NfL. To our knowledge this is the first time that a drug reduces the levels of TDP43 in humans, specifically here in PD patients,” said Dr. Maccecchini. “These biomarker data not only corroborate the mechanism of actions of buntanetap, but also provide a new way to stratify patients and understand their disease pathology. We will measure the above biomarkers in the plasma of the patients that are presently in our phase 3 PD study to show the effect our drug has on the course of the disease over a six-month period.”

businesswire.com/news/home/...

[Obiora]

Sounds really promising, i think the phase III trial results are set to be unveiled soon?

[Farooqji in reply to Obiora]

After two months or so

[WinnieThePoo in reply to Obiora]

The share price is underwhelmed by the news

[Pegcity in reply to WinnieThePoo]

Makes sense. The CEO has been talking about TDP43 for a while now. I guess the article was put out to support the public offering.

[MBAnderson]

Yesterday was my last Buntanetap pill and I'm sorry to see it go. Boo-hoo

[Jmellano in reply to MBAnderson]

@mbanderson Did u see a difference in your symptoms while on buntanetap (or placebo) during trial?

[MBAnderson in reply to Jmellano]

Yes, it relieved me of constipation at the end of the 3rd month.

[ProudParkie2017 in reply to MBAnderson]

I have all of my fingers crossed that they open label extension it. I have been off since July and feel so much worse! I would go back on in a heartbeat!!